Back to mobile site

BTIG Reiterates Buy Rating on INmune Bio Inc. (INMB)

September 18, 2024 6:22 AM EDT Send to a Friend
BTIG analyst Thomas Shrader reiterated a Buy rating and $21.00 price target on INmune Bio Inc. (NASDAQ: INMB)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login